Autres langues Atossa Therapeutics, Inc.

Actions

ATOS

US04962H7044

Recherche biotechnologique et médicale

Temps Différé Nasdaq 18:45:17 14/08/2026			Varia. 5j.	Varia. 1 janv.
2,580 ^USD	+0,78%		+9,32%	-70,85%

07/08	Atossa Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
28/07	Atossa Therapeutics annonce la publication de nouveaux composés dérivés du (Z)-endoxifène démontrant une activité anticancéreuse puissante dans le cancer du sein ER-positif	CI

Autres langues

07/08	Atossa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
28/07	Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in Er-Positive Breast Cancer
29/06	Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index
29/06	Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Index
29/06	Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Index
29/06	Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Growth Benchmark
29/06	Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Value Benchmark
29/06	Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Growth Benchmark Index
12/06	Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
11/06	Top Midday Decliners
11/06	Atossa Therapeutics Launches $16.5 Million Registered Direct Offering
27/05	Atossa Therapeutics Presents ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations And Ongoing EVANGELINE Phase 2 Trial
20/05	Atossa Therapeutics : Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
08/05	Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
04/05	Karolinska Institutet: New treatment with fewer side effects reduces breast density
04/05	Atossa Therapeutics receives FDA rare pediatric disease designation for (Z)-endoxifen for McCune-Albright Syndrome
04/05	Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For McCune-Albright Syndrome
25/03	Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
25/03	Atossa Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
19/03	Atossa Therapeutics, Inc. Appoints Kathy Puyana Theall, M.D. as Medical Director - Breast Oncology and Adebola Giwa, M.D. as Medical Director - Rare Diseases
12/03	Atossa Therapeutics, Inc. Presents Clinical Trial Update On Z-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
11/02	Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook
11/02	Atossa Therapeutics : Investor Presentation (image/ATOS IR Deck 11 FEB FINAL web version)
17/01	Stocks to Watch : Atossa Therapeutics, Union Pacific